ATTENTION NASDAQ: MGX INVESTORS: Contact Berger Montague About a Metagenomi Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its business prospects and relationship with Moderna during the specified class period [1][5]. Company Overview - Metagenomi Inc. is a genetic medicines company based in Emeryville, CA, with a significant collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The collaboration included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs [3]. Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which was a critical aspect of its business strategy [4]. - Following the announcement, Metagenomi's share price dropped from $7.04 to $6.17 within a day and continued to decline, trading slightly above $2.00 at the time of the lawsuit filing [4]. Legal Proceedings - The lawsuit claims that Metagenomi and its senior executives misled investors about the company's prospects, particularly concerning its relationship with Moderna [5]. - Investors who purchased Metagenomi securities during the class period can seek to be appointed as lead plaintiff representatives by November 25, 2024 [2].